Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

NCT03795428 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated: Study drug resupply delayed (Covid-19)

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Pemziviptadil (PB1046) Injection

Sponsor

PhaseBio Pharmaceuticals Inc.